Capstone Clinical Research

Libertyville, Illinois 60418

0 studies enrolling now · 54 studies all time

What they study most

ADHD, ADHD Specifically With Executive Function Impairment, Adjunctive Treatment of Major Depressive Disorder, Attention Deficit Disorder With Hyperactivity, Attention Deficit Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder (ADHD), Attention-Deficit/Hyperactivity Disorder, Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type, Attention-deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Binge Eating Disorder, Binge-Eating Disorder

Studies at this site

• Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder — Stopped early
• Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems — Completed
• A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy — Completed
• A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder — Completed
• Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment — Stopped early
• Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1) — Completed
• Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder — Completed
• Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment — Stopped early
• Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder — Completed
• Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD — Completed
• Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment — Completed
• KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD — Completed
• SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder — Completed
• Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl — Completed
• Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder — Completed
• Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) — Completed
• SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms — Completed
• Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder — Completed
• Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study — Completed
• Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate — Completed
• Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder — Completed
• Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder — Completed
• Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) — Completed
• Open Label Extension in Adults With Binge Eating Disorder (BED) — Completed
• Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder — Completed
• SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder — Completed
• Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD) — Completed
• A Study to Investigate the Efficacy and Safety of Balovaptan (RO5285119) in Participants With Autism Spectrum Disorder (ASD) — Stopped early
• Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD) — Stopped early
• Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD) — Stopped early
• Study of Rapastinel as Monotherapy in Patients With MDD — Stopped early
• Software Treatment for Actively Reducing Severity of ADHD — Completed
• Dasotraline Binge Eating Disorder Extension Study — Completed
• Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) — Stopped early
• A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder — Completed
• Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder — Completed
• Dasotraline Pediatric Extension Study — Completed
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02) — Completed
• Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22) — Completed
• A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder — Completed
• Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder — Completed
• Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia — Completed
• Dasotraline Binge Eating Disorder Study — Completed
• A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD) — Completed
• A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD — Completed
• A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity ) — Completed
• A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD — Completed
• Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy — Completed
• Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD) — Completed